Expression of the human erythrocyte glucose transporter in transitional cell carcinoma of the bladder

Chang, Sung‐Goo; Lee, Sun-Ju; Lee, Choong‐Hyun; Kim, Sang Hyun; Kim, Youn-Wha

doi:10.1016/s0090-4295(99)00474-4

Cited by 44 publications

(38 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other studies have demonstrated that GLUT1 expression is not seen in normal bladder mucosa, but is present in malignant bladder mucosa with greater expression seen in muscle-invasive tumours compared to superficial bladder cancer (Chang et al, 2000). In this study, there was no correlation between recurrence and GLUT1 expression.…”

Section: Discussioncontrasting

confidence: 63%

GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON

et al. 2003

View full text Add to dashboard Cite

Glucose transporter-1 protein (GLUT1) and carbonic anhydrase IX (CAIX) are regulated by hypoxia inducible factor-1 (HIF-1) and have been studied as putative intrinsic cellular markers for hypoxia. This study directly compares CAIX and GLUT1 with pimonidazole binding in a prospective series of bladder cancer patients and also studies the prognostic significance of the markers, in combination with vascularity and proliferation, in a retrospective series of bladder cancer patients treated in a phase II trial of radical radiotherapy with carbogen and nicotinamide (ARCON). A total of 21 patients with a diagnosis of transitional cell carcinoma of the bladder received 0.5 g m À2 pimonidazole. Serial tumour sections were stained for pimonidazole, GLUT1 and CAIX and compared. Tissue sections obtained from a series of 64 patients previously treated for invasive bladder cancer using ARCON were stained for GLUT1 and CAIX together with Ki-67 and CD31/34. There was a good geographical colocalisation of both intrinsic markers with pimonidazole and a highly significant agreement in individual patients; correlation coefficients were 0.82 (P ¼ 0.0001) for GLUT1 and 0.74 (Po0.0001) for CAIX. In both series of patients, the intrinsic hypoxia markers were highly correlated with each other and a correlation with proliferation was also evident in the retrospective study. In univariate and multivariate analyses, GLUT1 and CAIX were independent predictors for overall and cause specific survival. The hypoxia markers did not predict for local control or metastases-free survival although higher Ki-67 indices showed a trend towards local failure. The data suggest that both hypoxia modification and accelerated treatment may be valid treatment options in bladder cancer.

show abstract

Section: Discussioncontrasting

confidence: 63%

GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON

et al. 2003

View full text Add to dashboard Cite

show abstract

“…35 GLUT-1 expression has been revealed in a variety of carcinomas, such as those of the breast, head and neck, bladder, and renal cells. [15][16][17][18][19]23 In the lung, about 34.3-100% of lung adenocarcinomas 16,[20][21][22]24 and 100% of lung squamous cell carcinomas [20][21][22]24 are reported to express GLUT-1 at the primary site. With regard to MPM, only one article has describe that two of four studied cases were positive for GLUT-1.…”

Section: Discussionmentioning

confidence: 99%

“…15,16 In contrast, GLUT-1 is expressed in a variety of carcinomas such as those of the breast, head and neck, bladder, renal cells, and lung. [15][16][17][18][19][20][21][22][23][24] Previous reports suggest that the expression of GLUT-1 may be a potential marker for malignancy.…”

mentioning

confidence: 99%

Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma

et al. 2007

View full text Add to dashboard Cite

The separation of benign reactive mesothelium (RM) from malignant mesothelial proliferation can be a major challenge. A number of markers have been proposed, including epithelial membrane antigen, p53 protein, and P-glycoprotein. To date, however, no immunohistochemical marker that allows unequivocal discrimination of RM from malignant pleural mesothelioma (MPM) has been available. A family of glucose transporter isoforms (GLUT), of which GLUT-1 is a member, facilitate the entry of glucose into cells. GLUT-1 is largely undetectable by immunohistochemistry in normal epithelial tissues and benign tumors, but is expressed in a variety of malignancies. Thus, the expression of GLUT-1 appears to be a potential marker of malignant transformation. Recently, in fact, some studies have shown that GLUT-1 expression is useful for distinguishing benign from malignant lesions. The purpose of the present study was to evaluate the diagnostic utility of GLUT-1 expression for diagnostic differentiation between RM and MPM. Immunohistochemical staining for GLUT-1 was performed in 40 cases of RM, 48 cases of MPM, and 58 cases of lung carcinoma. Immunohistochemical GLUT-1 expression was seen in 40 of 40 (100%) MPMs, and in all cases the expression was demonstrated by linear plasma membrane staining, sometimes with cytoplasmic staining in addition. GLUT-1 expression was also observed in 56 out of 58 (96.5%) lung carcinomas. On the other hand, no RM cases were positive for GLUT-1. GLUT-1 is a sensitive and specific immunohistochemical marker enabling differential diagnosis of RM from MPM, whereas it cannot discriminate MPM from lung carcinoma. Modern Pathology (2007) 20, 215-220.

show abstract

“…In addition, GLUT1 protein expression is elevated in breast cancer (12), renal cell carcinoma (13), squamous cell carcinomas of the head and neck (14) and in carcinomas of various other sites (10). GLUT1 expression was found to be negative in normal bladder mucosa (15) and other non-neoplastic tissues (10). In contrast, a positive GLUT1 expression was reported to be present in the majority of urothelial urinary bladder carcinomas, including urothelial carcinoma of the renal pelvis (21), with varying effects on clinicopathological parameters (15,(17)(18)(19)(20)(21).…”

Section: Introductionmentioning

confidence: 99%

Expression of GLUT1 is associated with increasing grade of malignancy in non-invasive and invasive urothelial carcinomas of the bladder

et al. 2011

View full text Add to dashboard Cite

Abstract. Glucose Transporter 1 (GLUT1) belongs to the expanding mammalian facilitative glucose transporter family. Elevated GLUT1 protein expression has been observed in the majority of urothelial carcinomas, with various effects on clinicopathological parameters. Whereas malignant cells have an accelerated metabolism with increased energy requirements, the membranous expression of GLUTs is amplified. GLUT1 protein expression was evaluated in urothelial tumours of increasing grade of malignancy, supplemented by a tumour proliferation analysis. Particular attention was paid to non-invasive precursors of urothelial carcinoma. A total of 105 paraffin-embedded samples were classified (normal urothelium, low/high-grade papillary carcinoma, carcinoma in situ and invasive carcinoma). Grading and staging were conducted using the 1998 ISUP/2004 WHO criteria. The staining intensity of GLUT1 was assessed with a standard immunoreactive score (IRS). The Ki-67 index was assessed by counting positive nuclei in representative urothelial hot spots. Results showed that an increased GLUT1-IRS and mean count of Ki-67-positive cells were significantly associated with an increased grade of malignancy (p<0.0001), particularly in non-invasive tumours. GLUT1-IRS was significantly associated with a Ki-67-labelled proliferative fraction (p<0.0001). No significant association regarding tumour grade or stage was observed within the invasive carcinoma group. GLUT1 protein expression was found to be strongly correlated with increased malignant potential, particularly in non-invasive urothelial carcinomas. The increase of GLUT1 expression may reflect a preinvasive metabolic switch in terms of enhanced cell metabolism concomitant to known genetic alterations. A further increase in invasive carcinomas may be related to hypoxic conditions.

show abstract

Expression of the human erythrocyte glucose transporter in transitional cell carcinoma of the bladder

Cited by 44 publications

References 12 publications

GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON

GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON

Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma

Expression of GLUT1 is associated with increasing grade of malignancy in non-invasive and invasive urothelial carcinomas of the bladder

Contact Info

Product

Resources

About